EcoDrugPlus

Cytochrome P450 3a40-Like

Ensembl ID : ENSNBRG00000012065
Gene Symbol: LOC102796123
2 Cross references
518 Possible Orthologues:

Cytochrome P450 Family 19 Subfamily A Member 1

Ensembl ID : ENSNBRG00000012763
Gene Symbol: CYP19A1
4 Cross references
244 Possible Orthologues:

Cytochrome P450 Family 46 Subfamily A Member 1

Ensembl ID : ENSNBRG00000018823
Gene Symbol: CYP46A1
3 Cross references
240 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSNBRG00000008950
Gene Symbol: CYP3A65
1 Cross references
540 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSNBRG00000009111
Gene Symbol: CYP3A65
1 Cross references
541 Possible Orthologues:

Delta(24)-Sterol Reductase-Like

Ensembl ID : ENSNBRG00000000240
Gene Symbol: LOC102794897
3 Cross references
208 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSNBRG00000000698
Gene Symbol: LOC102799888
3 Cross references
179 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSNBRG00000013998
Gene Symbol: LOC102799815
3 Cross references
190 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1-Like

Ensembl ID : ENSNBRG00000014736
Gene Symbol: LOC102798903
3 Cross references
191 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone), Mitochondrial-Like

Ensembl ID : ENSNBRG00000016777
Gene Symbol: LOC102785818
3 Cross references
172 Possible Orthologues:

Dihydropyrimidine Dehydrogenase B

Ensembl ID : ENSNBRG00000001729
Gene Symbol: DPYDB
1 Cross references
210 Possible Orthologues:

Dipeptidyl Peptidase 1-Like

Ensembl ID : ENSNBRG00000014727
Gene Symbol: LOC102778921
3 Cross references
237 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).